Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is one such receptor, and its role as a key negative regulator of T-cell responses gives it the potential as a target for therapy in multiple cancer types [3, 4]. This evidence concerns the gene CTLA4 and cancer.